Endeavor BioMedicines Appoints Bill Bradford, M.D., Ph.D., to Board of Directors
September 12 2024 - 8:15AM
Business Wire
Endeavor BioMedicines, a clinical-stage biotechnology company
developing medicines with the potential to deliver transformational
clinical benefits to patients with life-threatening diseases, today
announced the appointment of Williamson “Bill” Bradford, M.D.,
Ph.D., to the company’s board of directors. Dr. Bradford brings
over two decades of industry experience to the board, including
executive leadership and clinical development expertise in
idiopathic pulmonary fibrosis (IPF).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240912134062/en/
Williamson "Bill" Bradford, M.D., Ph.D.
(Photo: Business Wire)
“As we advance the clinical program for ENV-101, our lead
investigational candidate in idiopathic pulmonary fibrosis, Dr.
Bradford’s extensive knowledge and background in fibrotic lung
disease – from the clinic to regulatory approval – will be an
invaluable resource to our team,” said John Hood, Ph.D.,
Co-Founder, CEO and Chairman, Endeavor. “He is widely recognized
for his executive and scientific leadership and we are honored to
welcome him to our Board of Directors.”
Dr. Bradford has more than 25 years of experience in the
biopharmaceutical industry in executive leadership, product
development, medical affairs, and board director roles. He is the
Principal at Teton Bioscience and has provided drug development and
strategic advisory services since 2015. He co-founded Indalo
Therapeutics, a clinical-stage fibrosis company, served as a Board
Director, and was Chief Medical Officer until 2020. Dr. Bradford
also served as Senior Vice President, Clinical Development at
InterMune, Inc. (acquired by Roche), where he led the successful
development of Esbriet® (pirfenidone), an FDA-approved medication
for the treatment of IPF and advanced a portfolio of therapeutics
in the clinic across a range of therapeutic areas. Earlier in his
career, Dr. Bradford held product development positions at
Genentech (member of the Roche Group) and IntraBiotics
Pharmaceuticals and was an infectious disease specialist and
researcher at the University of California, San Francisco.
“There is significant need to transform the current standard of
care and improve quality of life for patients with idiopathic
pulmonary fibrosis, and I believe Endeavor BioMedicines’ ENV-101
has the potential to change the trajectory of this life-threatening
disease,” said Dr. Bradford. “I look forward to helping the
Endeavor team accelerate the development of ENV-101 to bring this
exciting new treatment option to patients suffering from fibrotic
lung disease.”
About Endeavor BioMedicines
Endeavor BioMedicines is a clinical-stage biotechnology company
developing medicines with the potential to deliver transformational
clinical benefits to patients with life-threatening diseases.
Endeavor’s lead candidate, ENV-101 (taladegib), is an inhibitor of
the Hedgehog signaling pathway in clinical development for fibrotic
lung diseases, including idiopathic pulmonary fibrosis (IPF). The
company’s second candidate, ENV-501, is a HER3 antibody-drug
conjugate (ADC) for the treatment of HER3-positive solid tumors.
More information is available at www.endeavorbiomedicines.com and
on LinkedIn or X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240912134062/en/
Media:
Audra Friis Sam Brown, Inc. 917-519-9577
audrafriis@sambrown.com